SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Kleine Tebbe Jörg)
 

Sökning: WFRF:(Kleine Tebbe Jörg) > EAACI: A European D...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006198naa a2200865 4500
001oai:gup.ub.gu.se/196921
003SwePub
008240528s2012 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:223110958
0247 a https://gup.ub.gu.se/publication/1969212 URI
0247 a https://doi.org/10.1186/2045-7022-2-202 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2231109582 URI
040 a (SwePub)gud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Calderon, Moises A4 aut
2451 0a EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.
264 c 2012-10-30
264 1b Wiley,c 2012
520 a Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy.Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies.Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals' quality of life, reducing the long-term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of allergic diseases.Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits.We call upon Europe's policy-makers to coordinate actions and improve individual and public health in allergy by:Promoting awareness of the effectiveness of allergen specific immunotherapyUpdating national healthcare policies to support allergen specific immunotherapyPrioritising funding for allergen specific immunotherapy researchMonitoring the macroeconomic and health economic parameters of allergyReinforcing allergy teaching in medical disciplines and specialtiesThe effective implementation of the above policies has the potential for a major positive impact on European health and well-being in the next decade.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Lungmedicin och allergi0 (SwePub)302192 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Respiratory Medicine and Allergy0 (SwePub)302192 hsv//eng
7001 a Demoly, Pascal4 aut
7001 a Gerth van Wijk, Roy4 aut
7001 a Bousquet, Jean4 aut
7001 a Sheikh, Aziz4 aut
7001 a Frew, Anthony4 aut
7001 a Scadding, Glenis4 aut
7001 a Bachert, Clausu Karolinska Institutet4 aut
7001 a Malling, Hans J4 aut
7001 a Valenta, Rudolph4 aut
7001 a Bilo, Beatrice4 aut
7001 a Nieto, Antonio4 aut
7001 a Akdis, Cezmi4 aut
7001 a Just, Jocelyne4 aut
7001 a Vidal, Carmen4 aut
7001 a Varga, Eva M4 aut
7001 a Alvarez-Cuesta, Emilio4 aut
7001 a Bohle, Barbara4 aut
7001 a Bufe, Albrecht4 aut
7001 a Canonica, Walter G4 aut
7001 a Cardona, Victoria4 aut
7001 a Dahl, Ronald4 aut
7001 a Didier, Alain4 aut
7001 a Durham, Stephen R4 aut
7001 a Eng, Peter4 aut
7001 a Fernandez-Rivas, Montserrat4 aut
7001 a Jacobsen, Lars4 aut
7001 a Jutel, Marek4 aut
7001 a Kleine-Tebbe, Jörg4 aut
7001 a Klimek, Ludger4 aut
7001 a Lötvall, Jan,d 1956u Gothenburg University,Göteborgs universitet,Krefting Research Centre4 aut0 (Swepub:gu)xlotja
7001 a Moreno, Carmen4 aut
7001 a Mosges, Ralph4 aut
7001 a Muraro, Antonella4 aut
7001 a Niggemann, Bodo4 aut
7001 a Pajno, Giovanni4 aut
7001 a Passalacqua, Giovanni4 aut
7001 a Pfaar, Oliver4 aut
7001 a Rak, Sabina,d 19454 aut
7001 a Senna, Gianenrico4 aut
7001 a Senti, Gabriela4 aut
7001 a Valovirta, Erkka4 aut
7001 a van Hage, Marianne4 aut
7001 a Virchow, Johannes C4 aut
7001 a Wahn, Ulrich4 aut
7001 a Papadopoulos, Nikolaos4 aut
7102 a Karolinska Institutetb Krefting Research Centre4 org
7730 t Clinical and translational allergyd : Wileyg 2:1q 2:1x 2045-7022
8564 u https://ctajournal.biomedcentral.com/track/pdf/10.1186/2045-7022-2-20
8564 8u https://gup.ub.gu.se/publication/196921
8564 8u https://doi.org/10.1186/2045-7022-2-20
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:223110958

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy